Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide

References

• goldcopd.org. [homepage on the Internet]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2017 [updated 2017; cited Jan 18, 2018]. Available from: http://goldcopd.orgAccessed January 18, 2018
   Google Scholar
• SeemungalTADonaldsonGCBhowmikAJeffriesDJWedzichaJATime course and recovery of exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20001611608161310806163
   PubMed Web of Science ®Google Scholar
• StrasselsSASmithDHSullivanSDMahajanPSThe cost of treating COPD in the United StatesChest200111934435211171708
   PubMed Web of Science ®Google Scholar
• FitzGeraldJMHaddonJMBradly-KennedyCKuramotoLFordGTRUSIC Study GroupResource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patientsCan Respir J20071414515217464378
   PubMed Web of Science ®Google Scholar
• Miguel-DiezJJimenez-GarciaRHernandez-BarreraVTrends in hospital admissions for acute exacerbation of COPD in Spain from 2006 to 2010Respir Med201310771772323421969
   PubMed Web of Science ®Google Scholar
• HalpinDMGDecramerMCelliBDietteGBExacerbation frequency and course of COPDInt J Chron Obstruct Pulmon Dis2012765366123055714
   PubMed Web of Science ®Google Scholar
• PatilSPKrishnanJALechtzinNIn-hospital mortality following acute exacerbations of chronic obstructive pulmonary diseaseArch Intern Med20031631180118612767954
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J20032291291914680078
   PubMed Web of Science ®Google Scholar
  ErratumEur Respir J2004241075
   Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• SantusPDi MarcoFRadovanovicDCentanniSTiotropium: what came after the UPLIFT studyExpert Opin Pharmacother20121361361822283503
   PubMed Web of Science ®Google Scholar
• MiravitllesMAnzuetoAA new two-step algorithm for the treatment of COPDEur Respir J201749160079128298398
   PubMed Web of Science ®Google Scholar
• CooperCBBarjaktarevicIA new algorithm for the management of COPDLancet Respir Med2015326626825890644
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDSUMMIT InvestigatorsFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet20163871817182627203508
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med20143711285129425196117
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRFLAME InvestigatorsIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med20163742222223427181606
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMPavlisovaIMontagnaIFranciscoCSingle inhaler triple therapy versus inhaled corticosteroid plus long acting β-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trialLancet201638896397327598678
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet20173891919192928385353
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNIMPACT InvestigatorsOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med20183781671168029668352
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet20183911076108429429593
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• CazzolaMAndòFSantusPA pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPDPulm Pharmacol Ther20072055656116914336
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax20086359259818245142
   PubMed Web of Science ®Google Scholar
• HananiaNACraterGDMorrisANEmmettAHO’DellDMNiewoehnerDEBenefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPDRespir Med20121069110122040533
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlisten Study GroupGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax20157051952725841237
   PubMed Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHJLipworthSIWSchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest2012141818621799028
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trialAm J Respir Crit Care Med20171951189119728278391
   PubMed Web of Science ®Google Scholar
• AndersonGPFormoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilatorLife Sci199352214521608099696
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDPaggiaroPWhy use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterolEur J Intern Med20152637938426049917
   PubMed Web of Science ®Google Scholar
• AndersonGPLindénARabeKFWhy are long-acting beta-adrenoceptor agonists long-acting?Eur Respir J199475695787912202
   PubMed Web of Science ®Google Scholar
• LötvallJPalmqvistMArvidssonPMaloneyAVentrescaGPWardJThe therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patientsJ Allergy Clin Immunol200110872673111692096
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2 agonists therapy in lung diseaseAm J Resp Care Med2013187690696
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• IdaHCardiorespiratory activities of 3-formylamino-4-hydroxy – (N-1-methyl-2-p methoxyphenethylaminomethyl)-benzylalcohol-hemifumarate (BD 40A) and some other -adrenoceptor stimulants in conscious guinea pigsArzneimittelforschung1976261337134012766
   PubMed Web of Science ®Google Scholar
• LindénABergendalAUllmanASkooghBELöfdahlCGSalmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonismThorax1993485475538100652
   PubMed Web of Science ®Google Scholar
• NalineEZhangYQianYRelaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchusEur Respir J199479149207914176
   PubMed Web of Science ®Google Scholar
• CazzolaMCentanniSRegordaCOnset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPDPulm Pharmacol Ther200114414511162418
   PubMed Web of Science ®Google Scholar
• Di MarcoFVergaMSantusPMorelliNCazzolaMCentanniSEffect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot studyRespir Med20061001925193216626956
   PubMed Web of Science ®Google Scholar
• NialsATBallDIButchersPRFormoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterolEur J Pharmacol19942511271358149969
   PubMed Web of Science ®Google Scholar
• BanfiPTicozziNLaxAGuidugliGANicoliniASilaniVA review of options for treating sialorrhea in amyotrophic lateral sclerosisRespir Care20156044645425228780
   PubMed Web of Science ®Google Scholar
• BlissitKTTilleryELathamCPacheco-PerezJGlycopyrrolate for treatment of clozapine-induced sialorrhea in adultsAm J Health Syst Pharm2014711282128725027535
   PubMed Web of Science ®Google Scholar
• pubchem.ncbi.nlm.nih.gov [homepage on the Internet]Pub Chem, Open Chemistry DatabaseNational Center for Biotechnology Information; US National Library of Medicine2005 [updated May 19, 2018]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/glycopyrrolateLast accessed May 15, 2018
   Google Scholar
• CarterNJInhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary diseaseDrugs20137374175323677802
   PubMed Web of Science ®Google Scholar
• SechaudRRenardDZhang-AubersonLMotte SdeLDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther20125011812822257577
   PubMed Web of Science ®Google Scholar
• UlrikCSOnce-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefitInt J Chron Obstruct Pulmon Dis2012767367823055716
   PubMed Web of Science ®Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772973423118536
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRLeighton-DaviesJThe influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropiumJ Pharmacol Exp Ther201234352052822854200
   PubMed Web of Science ®Google Scholar
• VerkindreCFukuchiYFlémaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med20101041482148920541381
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDDi MarcoFRaccanelliRValentiVCentanniSFaster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover studyPulm Pharmacol Ther201535424926549785
   PubMed Web of Science ®Google Scholar
• VillettiGBergamaschiMBassaniFPharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airwaysBr J Pharmacol200614829129816565730
   PubMed Web of Science ®Google Scholar
• Daley-YatesPTPriceACSissonJRBeclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBr J Clin Pharmacol20015140040911421996
   PubMed Web of Science ®Google Scholar
• LeachCLDavidsonPJHasselquistBELung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteersChest200212251051612171824
   PubMed Web of Science ®Google Scholar
• BoobisARComparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonideRespir Med199892Suppl B2610193529
   PubMed Web of Science ®Google Scholar
• HübnerMHochhausGDerendorfHComparative pharmacology, bio-availability, pharmacokinetics, and pharmacodynamics of inhaled gluco-corticosteroidsImmunol Allergy Clin North Am20052546948816054538
   PubMed Web of Science ®Google Scholar
• BhattSPSolerXWangXCOPDGene InvestigatorsAssociation between functional small airway disease and FEV1 decline in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201619417818426808615
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDDi MarcoSEffect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trialInt J Chron Obstruct Pulmon Dis2015101917192326392766
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDHenchiSAssessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patientsRespir Physiol Neurobiol2014197364524726342
   PubMed Web of Science ®Google Scholar
• PecchiariMSantusPRadovanovicDD’AngeloEAcute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curveJ Appl Physiol (1985)20171231266127528775071
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapyCurr Opin Pharmacol2018409510329626716
   PubMed Web of Science ®Google Scholar
• SinghDSchröder-BaboWCohuetGTRIDENT Study InvestigatorsThe bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: a randomised crossover study (the TRIDENT study)Respir Med2016114849027109816
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGFaccioloFCazzolaMRoglianiPBeclomethasone dipropionate and formoterol fumarate synergistically interact in hyper-responsive medium bronchi and small airwaysRespir Res2018196529650006
   PubMed Web of Science ®Google Scholar
• SinghDCorradiMSpinolaMTriple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromideInt J Chron Obstruct Pulmon Dis2017122917292829062229
   PubMed Web of Science ®Google Scholar
• goldcopd.org. [homepage on the Internet]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2018 [updated 2018, cited May 18, 2018]. Available from: http://goldcopd.orgAccessed May 19, 2018
   Google Scholar
• Pearl Therapeutics, IncA study to assess the efficacy and safety of PT009 compared to PT005 on COPD exacerbations over a 52-week period in subjects with moderate to very severe COPD (Sophos) Available from: https://clinicaltrials.gov/ct2/show/NCT2727660. NLM identifier: NCT2727660Accessed May 20, 2018
   Google Scholar
• Chiesi Farmaceutici S.p.AActive controlled trial of CHF5993 pressurized metered-dose inhaler (pMDI) vs Symbicort^®Turbuhaler^® in patients with chronic obstructive pulmonary disease (COPD) (TRIVERSYTI) Available from: https://clinicaltrials.gov/ct2/show/NCT3197818?term=NCT3197818&rank=1. NLM identifier: NCT3197818Accessed May 20, 2018
   Google Scholar
• Pearl Therapeutics, IncStudy to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (Ethos) Available from: https://clinicaltrials.gov/ct2/show/NCT2465567. NLM identifier: NCT2465567Accessed May 20, 2018
   Google Scholar
• Boehringer IngelheimAssessment in a real world setting of the effect of inhaled steroid-based triple therapy versus the combination of tiotropium and olodaterol on reducing chronic obstructive pulmonary disease (COPD) exacerbations [AIRWISE] Available from: https://clinicaltrials.gov/ct2/show/NCT3265145. NLM identifier: NCT3265145Accessed May 20, 2018
   Google Scholar
• ChapmanKRHurstJRFrentSLong-term triple therapy deescalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med Epub2018520
   Web of Science ®Google Scholar
• CalverleyPMAA light in the darkness? The FLAME trial, blood eosinophils, and chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20171951125112728459328
   PubMed Web of Science ®Google Scholar